Dyne Therapeutics Inc (DYN) EPS is poised to hit -0.94 next quarter: How Investors Can Make It Count the Most?

Dyne Therapeutics Inc (NASDAQ: DYN) open the trading on Wednesday, with a bit cautious approach as it glided -6.12% to $24.56, before settling in for the price of $26.16 at the close. Taking a more long-term approach, DYN posted a 52-week range of $11.66-$47.45.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

It was noted that the giant of the Healthcare sector posted annual sales growth of 0.00% over the last 5 years. Meanwhile, its Annual Earning per share during the time was -106.26%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 12.22%. This publicly-traded company’s shares outstanding now amounts to $101.75 million, simultaneously with a float of $77.75 million. The organization now has a market capitalization sitting at $2.50 billion. At the time of writing, stock’s 50-day Moving Average stood at $30.00, while the 200-day Moving Average is $32.71.

Dyne Therapeutics Inc (DYN) Ownership Facts and Figures

Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Dyne Therapeutics Inc’s current insider ownership accounts for 23.60%, in contrast to 86.84% institutional ownership. According to the most recent insider trade that took place on Dec 11 ’24, this organization’s Chief Scientific Officer sold 2,334 shares at the rate of 28.12, making the entire transaction reach 65,632 in total value, affecting insider ownership by 201,685. Preceding that transaction, on Dec 11 ’24, Company’s SVP, Head of Finance & Admin. sold 1,455 for 28.12, making the whole transaction’s value amount to 40,915. This particular insider is now the holder of 127,078 in total.

Dyne Therapeutics Inc (DYN) Earnings and Revenue Records

Dyne Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 12.22% and is forecasted to reach -3.77 in the upcoming year.

Dyne Therapeutics Inc (NASDAQ: DYN) Trading Performance Indicators

Let’s observe the current performance indicators for Dyne Therapeutics Inc (DYN). It’s Quick Ratio in the last reported quarter now stands at 17.02. The Stock has managed to achieve an average true range (ATR) of 1.71.

In the same vein, DYN’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.56, a figure that is expected to reach -0.94 in the next quarter, and analysts are predicting that it will be -3.77 at the market close of one year from today.

Technical Analysis of Dyne Therapeutics Inc (DYN)

[Dyne Therapeutics Inc, DYN] recent stats showed that its last 5-days Average volume was poorer than the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 16.64% While, its Average True Range was 1.65.

Raw Stochastic average of Dyne Therapeutics Inc (DYN) in the period of the previous 100 days is set at 4.24%, which indicates a major rise in contrast to 3.58% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 59.09% that was lower than 80.88% volatility it exhibited in the past 100-days period.